Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00710580

Enrollment

350

Registered

2008-07-04

Start date

2008-07-31

Completion date

2009-04-30

Last updated

2013-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate to Severe Plaque Psoriasis

Brief summary

Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis

Interventions

BIOLOGICALABT-874

SQ injection 200 mg Weeks 0 and 4; 100 mg Week 8

BIOLOGICALetanercept

SQ injection 50 mg BIW

DRUGplacebo

SQ placebo injections for ABT-874 and etanercept

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosis of Psoriasis for 6 MO * BSA 10% * PASI 12 or above * PGA 3 or above

Exclusion criteria

* Previous exposure to either etanercept or ABT-874

Design outcomes

Primary

Measure	Time frame
Proportion of subjects who achieve a PGA of 0 or 1 response relative to baseline at Week 12	12 Weeks
Proportion of subjects who achieve a PASI 75 response relative to baseline at Week 12	12 Weeks

Secondary

Measure	Time frame
Proportion of subjects who achieve a PASI 100 response relative to baseline at Week 12	12 Weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026